Zila tries again with new oral cancer test protocol
This article was originally published in Clinica
Zila has submitted a new protocol for an additional clinical study of its oral cancer test to the US FDA. Data from the new study will be used to amend the company's previous drug application for the OraTest oral rinse, which failed to win backing from an FDA panel earlier this year (see Clinica 842, p 13).
You may also be interested in...
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.
In second letter this year targeting email communications, OPDP says that putting the methotrexate oral solution’s risk information below the signature block does not offer ‘prominence and readability’ comparable to the information on the drug’s effectiveness for the treatment of acute lymphoblastic leukemia that was in the body of the email.